|
|
Blood, 15 November 2004, Vol. 104, No. 10, pp. 3386-3392.
Prepublished online as a Blood First Edition Paper on July 13, 2004; DOI 10.1182/blood-2004-03-1155.
 Previous Article | Next Article 
Submitted March 26, 2004
Accepted June 3, 2004
Neuropsychological changes from pretransplant to one year in patients receiving myeloablative allogeneic hematopoietic cell transplant
Karen L Syrjala*, Sureyya Dikmen, Shelby Langer, Sari Roth-Roemer, and Janet Abrams
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA
Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA, USA
* Corresponding author; email: ksyrjala{at}fhcrc.org.
Research indicates that myeloablative hematopoietic cell transplant (HCT) impairs neurocognitive function. However, prospective studies on long-term effects are lacking. This longitudinal study examined neurocognitive changes over the first year in 142 adult allogeneic HCT recipients who received neuropsychological testing pretransplant and again after 80 days and one year. Age, gender and education-adjusted population-based standardized scores were used for normative comparisons. Performance on all tests declined from pretransplant to 80 days (P < .05) and improved by one year (P < .05), returning to pretransplant levels on all tests except for grip strength and motor dexterity. Although verbal fluency and memory recovered by one year, both were below norms at all three testing times (P < .01). Logistic regressions indicated that patients without chemotherapy, other than hydroxyurea, previous to HCT and patients not receiving chronic GVHD medication at one year had lower risk of impaired function (P < .05). In conclusion, HCT was associated with significant generalized decline in neurocognitive performance at 80 days, with subsequent recovery to pretransplant levels by one year for most survivors, except on motor tasks. Results indicate that long-term cognitive decrements, as distinct from motor disabilities, infrequently derive directly from HCT.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Cognitive side effects of myeloablative allogeneic hematopoietic cell transplantation
- Tim A. Ahles
Blood 2004 104: 3003-3004.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. A. Friedman, M. Fernandez, J. S. Wefel, K. A. Myszka, R. E. Champlin, and C. A. Meyers
Course of Cognitive Decline in Hematopoietic Stem Cell Transplantation: A Within-subjects Design
Arch Clin Neuropsychol,
November 1, 2009;
24(7):
689 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pidala, C. Anasetti, and H. Jim
Quality of life after allogeneic hematopoietic cell transplantation
Blood,
July 2, 2009;
114(1):
7 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.J.H. Mathews, J. Sugarman, H. Bok, D. M. Blass, J. T. Coyle, P. Duggan, J. Finkel, H. T. Greely, A. Hillis, A. Hoke, et al.
Cell-based interventions for neurologic conditions: Ethical challenges for early human trials
Neurology,
July 22, 2008;
71(4):
288 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Syrjala, B. F. Kurland, J. R. Abrams, J. E. Sanders, and J. R. Heiman
Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years
Blood,
February 1, 2008;
111(3):
989 - 996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Fann, C. M. Alfano, S. Roth-Roemer, W. J. Katon, and K. L. Syrjala
Impact of Delirium on Cognition, Distress, and Health-Related Quality of Life After Hematopoietic Stem-Cell Transplantation
J. Clin. Oncol.,
April 1, 2007;
25(10):
1223 - 1231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Syrjala, S. L. Langer, J. R. Abrams, B. E. Storer, and P. J. Martin
Late Effects of Hematopoietic Cell Transplantation Among 10-Year Adult Survivors Compared With Case-Matched Controls
J. Clin. Oncol.,
September 20, 2005;
23(27):
6596 - 6606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
